MedTrace Logo

EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA

NCT06787846 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-01-22

No results posted yet for this study

Summary

This study aims at assessing the non-inferiority of tested formula facial serum (2039125 03) versus hydroquinone 4% over 3 months for treatment and then 3 months for maintenance ofwomen subjects presenting facial melasma.

Conditions

  • Melasma

Interventions

OTHER

Experimental: Group TP

Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day

DRUG

Active Comparator: Group HQ: Hydroquinone 4%

Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day

Sponsors & Collaborators

  • Cosmetique Active International

    lead INDUSTRY

Principal Investigators

  • Renato Moura · CIDP

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2024-03-12
Completion
2024-03-12

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06787846 on ClinicalTrials.gov